{"filing":{"accession_number":"0001193125-26-266688","cik":"0001768446","ticker":"CLYM","company_name":"Climb Bio, Inc.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"d63753d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526266688/d63753d8k.htm"},"events":[{"id":5334,"run_id":4672,"accession_number":"0001193125-26-266688","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"This disclosure announces initial Phase 1b clinical trial data for budoprutug in primary ITP, showing favorable safety and efficacy signals (90% B-cell depletion, platelet responses in 4/6 patients at 250 mg dose, no serious adverse events). While clinical trial progress is material to a biotech company's valuation and investor assessment, it does not fit neatly into the standard 8-K event taxonomy (not an earnings release, M\u0026A activity, restatement, or other defined categories). The data supports continued development and is clearly significant to investors, warranting classification as other_material.","company_name":"Climb Bio, Inc.","ticker":"CLYM","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6083,"accession_number":"0001193125-26-266688","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"This disclosure announces initial Phase 1b clinical trial data for budoprutug in primary ITP, showing favorable safety and efficacy signals (90% B-cell depletion, platelet responses in 4/6 patients at 250 mg dose, no serious adverse events). While clinical trial progress is material to a biotech company's valuation and investor assessment, it does not fit neatly into the standard 8-K event taxonomy (not an earnings release, M\u0026A activity, restatement, or other defined categories). The data supports continued development and is clearly significant to investors, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T11:14:06.603449+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6083,"accession_number":"0001193125-26-266688","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"This disclosure announces initial Phase 1b clinical trial data for budoprutug in primary ITP, showing favorable safety and efficacy signals (90% B-cell depletion, platelet responses in 4/6 patients at 250 mg dose, no serious adverse events). While clinical trial progress is material to a biotech company's valuation and investor assessment, it does not fit neatly into the standard 8-K event taxonomy (not an earnings release, M\u0026A activity, restatement, or other defined categories). The data supports continued development and is clearly significant to investors, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T11:14:06.603449+00:00","company_name":"Climb Bio, Inc.","ticker":"CLYM","filing_date":"2026-06-11"}]}